miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer
Our previous study found that miR-145 was downregulated in non-small cell lung cancer (NSCLC) tissues and that it could inhibit the cell proliferation in transfected NSCLC cells. In this study, we found that miR-145 was downregulated in NSCLC plasma samples compared to healthy controls. A receiver o...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2023-06, Vol.24 (12), p.10022 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 10022 |
| container_title | International journal of molecular sciences |
| container_volume | 24 |
| creator | Cho, William C Wong, Chi F Li, Kwan P Fong, Alvin H Fung, King Y Au, Joseph S |
| description | Our previous study found that miR-145 was downregulated in non-small cell lung cancer (NSCLC) tissues and that it could inhibit the cell proliferation in transfected NSCLC cells. In this study, we found that miR-145 was downregulated in NSCLC plasma samples compared to healthy controls. A receiver operating characteristic curve analysis indicated that plasma miR-145 expression was correlated with NSCLC in patient samples. We further revealed that the transfection of miR-145 inhibited the proliferation, migration, and invasion of NSCLC cells. Most importantly, miR-145 significantly delayed the tumor growth in a mouse model of NSCLC. We further identified
and
as the direct targets of miR-145. A cohort of paired tumors and adjacent non-malignant lung tissues from NSCLC patients was used to confirm the downregulated expression and diagnostic value of miR-145. The results were highly consistent between our plasma and tissue cohorts, confirming the clinical value of miR-145 in different sample groups. In addition, we also validated the expressions of miR-145,
, and
using the TCGA database. Our findings suggested that miR-145 is a regulator of NSCLC and it plays an important role in NSCLC progression. This microRNA and its gene targets may serve as potential biomarkers and novel molecular therapeutic targets in NSCLC patients. |
| doi_str_mv | 10.3390/ijms241210022 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10298104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A758316530</galeid><sourcerecordid>A758316530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-f2547d9a2bdb52999053251bc4b34966da39ef4025c0c6a7eb9c86e6349716f43</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqVw5IosceGS4q848QmVFYVKq1LBcrYmjrPrJbEXOwH13zOrlraLKku25Xnm9bz2FMVrRk-F0PS9346ZS8YZpZw_KY6Z5LykVNVPH-yPihc5b5EQvNLPiyNR42BKHxd29N9KJisCmQC5ipMLk4eBfPRxhPTTJQKhI6uNS7Bz8-QtWUFau4n4QK5g8ohn8sdPG3IZQ_l9hGEgC4fTcg5rsoBgXXpZPOthyO7V7XpS_Dj_tFp8KZdfP18szpallY2Yyp5Xsu408LZrK661phWWy1orWyG1Uh0I7XpJeWWpVVC7VttGOYXBmqleipPiw43ubm5H11msLcFgdsmjlWsTwZvDSPAbs46_DaNcN4zuFd7dKqT4a3Z5MqPPFu1AcHHOhjeCKqUYrxF9-x-6jXMK6A8plBMSC7un1jA440Mf8WK7FzVnddXgH1SCInX6CIWjc6O3Mbje4_lBQnmTYFPMObn-ziSjZt8W5qAtkH_z8GXu6H99IP4CRWSwMA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829834634</pqid></control><display><type>article</type><title>miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cho, William C ; Wong, Chi F ; Li, Kwan P ; Fong, Alvin H ; Fung, King Y ; Au, Joseph S</creator><creatorcontrib>Cho, William C ; Wong, Chi F ; Li, Kwan P ; Fong, Alvin H ; Fung, King Y ; Au, Joseph S</creatorcontrib><description>Our previous study found that miR-145 was downregulated in non-small cell lung cancer (NSCLC) tissues and that it could inhibit the cell proliferation in transfected NSCLC cells. In this study, we found that miR-145 was downregulated in NSCLC plasma samples compared to healthy controls. A receiver operating characteristic curve analysis indicated that plasma miR-145 expression was correlated with NSCLC in patient samples. We further revealed that the transfection of miR-145 inhibited the proliferation, migration, and invasion of NSCLC cells. Most importantly, miR-145 significantly delayed the tumor growth in a mouse model of NSCLC. We further identified
and
as the direct targets of miR-145. A cohort of paired tumors and adjacent non-malignant lung tissues from NSCLC patients was used to confirm the downregulated expression and diagnostic value of miR-145. The results were highly consistent between our plasma and tissue cohorts, confirming the clinical value of miR-145 in different sample groups. In addition, we also validated the expressions of miR-145,
, and
using the TCGA database. Our findings suggested that miR-145 is a regulator of NSCLC and it plays an important role in NSCLC progression. This microRNA and its gene targets may serve as potential biomarkers and novel molecular therapeutic targets in NSCLC patients.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms241210022</identifier><identifier>PMID: 37373169</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Cell adhesion & migration ; Cell cycle ; Cell growth ; Cell proliferation ; Comparative analysis ; Down-regulation ; Health aspects ; Lung cancer ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Metastasis ; MicroRNA ; MicroRNAs ; miRNA ; Non-small cell lung carcinoma ; Plasma ; Plasmids ; Therapeutic applications ; Therapeutic targets ; Transfection ; Tumorigenesis ; Tumors</subject><ispartof>International journal of molecular sciences, 2023-06, Vol.24 (12), p.10022</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-f2547d9a2bdb52999053251bc4b34966da39ef4025c0c6a7eb9c86e6349716f43</citedby><cites>FETCH-LOGICAL-c483t-f2547d9a2bdb52999053251bc4b34966da39ef4025c0c6a7eb9c86e6349716f43</cites><orcidid>0009-0005-1251-0141 ; 0000-0003-4174-4586 ; 0000-0002-1512-5258</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298104/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298104/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37373169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cho, William C</creatorcontrib><creatorcontrib>Wong, Chi F</creatorcontrib><creatorcontrib>Li, Kwan P</creatorcontrib><creatorcontrib>Fong, Alvin H</creatorcontrib><creatorcontrib>Fung, King Y</creatorcontrib><creatorcontrib>Au, Joseph S</creatorcontrib><title>miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Our previous study found that miR-145 was downregulated in non-small cell lung cancer (NSCLC) tissues and that it could inhibit the cell proliferation in transfected NSCLC cells. In this study, we found that miR-145 was downregulated in NSCLC plasma samples compared to healthy controls. A receiver operating characteristic curve analysis indicated that plasma miR-145 expression was correlated with NSCLC in patient samples. We further revealed that the transfection of miR-145 inhibited the proliferation, migration, and invasion of NSCLC cells. Most importantly, miR-145 significantly delayed the tumor growth in a mouse model of NSCLC. We further identified
and
as the direct targets of miR-145. A cohort of paired tumors and adjacent non-malignant lung tissues from NSCLC patients was used to confirm the downregulated expression and diagnostic value of miR-145. The results were highly consistent between our plasma and tissue cohorts, confirming the clinical value of miR-145 in different sample groups. In addition, we also validated the expressions of miR-145,
, and
using the TCGA database. Our findings suggested that miR-145 is a regulator of NSCLC and it plays an important role in NSCLC progression. This microRNA and its gene targets may serve as potential biomarkers and novel molecular therapeutic targets in NSCLC patients.</description><subject>Biomarkers</subject><subject>Cell adhesion & migration</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell proliferation</subject><subject>Comparative analysis</subject><subject>Down-regulation</subject><subject>Health aspects</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Metastasis</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Non-small cell lung carcinoma</subject><subject>Plasma</subject><subject>Plasmids</subject><subject>Therapeutic applications</subject><subject>Therapeutic targets</subject><subject>Transfection</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEoqVw5IosceGS4q848QmVFYVKq1LBcrYmjrPrJbEXOwH13zOrlraLKku25Xnm9bz2FMVrRk-F0PS9346ZS8YZpZw_KY6Z5LykVNVPH-yPihc5b5EQvNLPiyNR42BKHxd29N9KJisCmQC5ipMLk4eBfPRxhPTTJQKhI6uNS7Bz8-QtWUFau4n4QK5g8ohn8sdPG3IZQ_l9hGEgC4fTcg5rsoBgXXpZPOthyO7V7XpS_Dj_tFp8KZdfP18szpallY2Yyp5Xsu408LZrK661phWWy1orWyG1Uh0I7XpJeWWpVVC7VttGOYXBmqleipPiw43ubm5H11msLcFgdsmjlWsTwZvDSPAbs46_DaNcN4zuFd7dKqT4a3Z5MqPPFu1AcHHOhjeCKqUYrxF9-x-6jXMK6A8plBMSC7un1jA440Mf8WK7FzVnddXgH1SCInX6CIWjc6O3Mbje4_lBQnmTYFPMObn-ziSjZt8W5qAtkH_z8GXu6H99IP4CRWSwMA</recordid><startdate>20230612</startdate><enddate>20230612</enddate><creator>Cho, William C</creator><creator>Wong, Chi F</creator><creator>Li, Kwan P</creator><creator>Fong, Alvin H</creator><creator>Fung, King Y</creator><creator>Au, Joseph S</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0005-1251-0141</orcidid><orcidid>https://orcid.org/0000-0003-4174-4586</orcidid><orcidid>https://orcid.org/0000-0002-1512-5258</orcidid></search><sort><creationdate>20230612</creationdate><title>miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer</title><author>Cho, William C ; Wong, Chi F ; Li, Kwan P ; Fong, Alvin H ; Fung, King Y ; Au, Joseph S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-f2547d9a2bdb52999053251bc4b34966da39ef4025c0c6a7eb9c86e6349716f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Cell adhesion & migration</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell proliferation</topic><topic>Comparative analysis</topic><topic>Down-regulation</topic><topic>Health aspects</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Metastasis</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Non-small cell lung carcinoma</topic><topic>Plasma</topic><topic>Plasmids</topic><topic>Therapeutic applications</topic><topic>Therapeutic targets</topic><topic>Transfection</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, William C</creatorcontrib><creatorcontrib>Wong, Chi F</creatorcontrib><creatorcontrib>Li, Kwan P</creatorcontrib><creatorcontrib>Fong, Alvin H</creatorcontrib><creatorcontrib>Fung, King Y</creatorcontrib><creatorcontrib>Au, Joseph S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, William C</au><au>Wong, Chi F</au><au>Li, Kwan P</au><au>Fong, Alvin H</au><au>Fung, King Y</au><au>Au, Joseph S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2023-06-12</date><risdate>2023</risdate><volume>24</volume><issue>12</issue><spage>10022</spage><pages>10022-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Our previous study found that miR-145 was downregulated in non-small cell lung cancer (NSCLC) tissues and that it could inhibit the cell proliferation in transfected NSCLC cells. In this study, we found that miR-145 was downregulated in NSCLC plasma samples compared to healthy controls. A receiver operating characteristic curve analysis indicated that plasma miR-145 expression was correlated with NSCLC in patient samples. We further revealed that the transfection of miR-145 inhibited the proliferation, migration, and invasion of NSCLC cells. Most importantly, miR-145 significantly delayed the tumor growth in a mouse model of NSCLC. We further identified
and
as the direct targets of miR-145. A cohort of paired tumors and adjacent non-malignant lung tissues from NSCLC patients was used to confirm the downregulated expression and diagnostic value of miR-145. The results were highly consistent between our plasma and tissue cohorts, confirming the clinical value of miR-145 in different sample groups. In addition, we also validated the expressions of miR-145,
, and
using the TCGA database. Our findings suggested that miR-145 is a regulator of NSCLC and it plays an important role in NSCLC progression. This microRNA and its gene targets may serve as potential biomarkers and novel molecular therapeutic targets in NSCLC patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37373169</pmid><doi>10.3390/ijms241210022</doi><orcidid>https://orcid.org/0009-0005-1251-0141</orcidid><orcidid>https://orcid.org/0000-0003-4174-4586</orcidid><orcidid>https://orcid.org/0000-0002-1512-5258</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2023-06, Vol.24 (12), p.10022 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10298104 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Cell adhesion & migration Cell cycle Cell growth Cell proliferation Comparative analysis Down-regulation Health aspects Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Metastasis MicroRNA MicroRNAs miRNA Non-small cell lung carcinoma Plasma Plasmids Therapeutic applications Therapeutic targets Transfection Tumorigenesis Tumors |
| title | miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A31%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-145%20as%20a%20Potential%20Biomarker%20and%20Therapeutic%20Target%20in%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Cho,%20William%20C&rft.date=2023-06-12&rft.volume=24&rft.issue=12&rft.spage=10022&rft.pages=10022-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms241210022&rft_dat=%3Cgale_pubme%3EA758316530%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829834634&rft_id=info:pmid/37373169&rft_galeid=A758316530&rfr_iscdi=true |